USAID Approves MedMira's CE Marked Reveal HIV Test

    




 HALIFAX, April 4, 2012 /CNW/ - MedMira Inc., (MedMira) , a  developer of rapid diagnostic technology and solutions, announced today  that the Company's most advanced rapid HIV test, Reveal HIV, has been  approved by the United States Agency for International Development  (USAID) for inclusion on its list of approved rapid HIV tests. 

 Since its inception in 1986, the USAID HIV/AIDS program has invested  over $7 billion to fight this global crisis.  USAID is a key partner in  the U.S. President's Emergency Plan for AIDS Relief (PEPFAR), the largest and most diverse HIV/AIDS prevention, care, and  treatment initiative in the world. 

 With this approval and listing, MedMira's CE-marked rapid HIV tests, in  addition to the previously listed FDA-approved rapid HIV test, are  eligible for procurement with funds provided by USAID.  This new  approval further strengthens the Company's global rapid HIV test  product line and serves as a strong foundation for MedMira to bring  forward its other rapid diagnostic product lines, including Multiplo,  for similar programs and approvals. 

 "We are very pleased with this latest approval and MedMira will continue  to expand upon its portfolio of products within organizations such as  USAID and PEPFAR in order to meet the increasing global demand,  particularly in developing countries, for high quality rapid  diagnostics," said Hermes Chan, CEO, MedMira Inc.  "With the addition  of three formats of MedMira's CE-marked rapid HIV test, projects funded  by USAID and PEPFAR will be able to select the right format of the  product for their testing initiative and further global HIV prevention  and control efforts." 

 Organizations purchasing Reveal HIV from the approved USAID list can now  select the format and packaging that best suits their program needs.   The various Reveal HIV product configurations available through USAID  offer customers choice, flexibility and convenience whether their  testing program is taking place in a hospital setting, a voluntary  testing clinic, or through a mobile testing vehicle. 

 Chan continued, "The Reveal HIV product line satisfies the needs of a  broad range of USAID sponsored testing programs.  Resource-constrained  testing programs can use the convenient and cost-effective all-in-one  package for fingerstick, point-of-care testing while reference  laboratories and other clinical settngs can use the veni-puncture whole  blood/serum/plasma formats for batch testing.  The two laboratory  formats offer customers significantly decreased administrative costs  and testing time, a key advantage over other rapid HIV testing  technology in large scale, government screening programs." 

 About MedMira 

 MedMira is a leading developer and manufacturer of flow-through rapid  diagnostics. The company's tests provide hospitals, labs, clinics and  individuals with reliable, rapid diagnosis for diseases such as HIV and  hepatitis C in just three minutes. The company's tests are sold under  the Reveal®, Multiplo™ and Miriad brands in global markets. MedMira's  rapid flow-through HIV test is the only one in the world to achieve  regulatory approvals in Canada, the United States, China and the  European Union. MedMira's corporate offices and manufacturing  facilities are located in Halifax, Nova Scotia, Canada. For more  information visit MedMira's website at www.medmira.com. 

 This news release contains forward-looking statements, which involve  risk and uncertainties and reflect the Company's current expectation  regarding future events including statements regarding possible future  growth and new business opportunities.  Actual events could materially  differ from those projected herein and depend on a number of factors  including, but not limited to, changing market conditions, successful  and timely completion of clinical studies, uncertainties related to the  regulatory approval process, establishment of corporate alliances and  other risks detailed from time to time in the company quarterly  filings. 

 Neither TSX Venture Exchange nor its Regulation Services Provider (as  that term is defined in the policies of the TSX Venture Exchange)  accepts responsibility for the adequacy or accuracy of this release. 

MEDMIRA INC.


CONTACT:  MedMira Contact:Andrea Young, Corporate CommunicationsTel: 902-450-1588Email: [e-mail] 


    

Copyright